PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
-
Trump says will fire Fed chair if he stays beyond mandate
-
Donors pledge 1.3 bn euros as Sudan marks three years of war
-
World Bank announces water security plan covering one billion people
-
Man Utd's Maguire out of Chelsea match after extra one-game ban
-
Oil rises, stocks mixed as investors eye chances for end of Mideast war
-
Doubles champion Jamie Murray retires from tennis
-
Merz praises Lufthansa on centenary as strikes ruin party
-
France's Gulf veteran minehunter patrols Channel
-
Brazil Supreme Court orders probe into Flavio Bolsonaro for 'slander' of Lula
-
IMF chief warns of 'tough times' if oil prices stay high
-
Bosnia approves gas project by Trump-linked investors
-
Pupil kills nine, wounds 13 in new Turkey school shooting
-
Left-wing candidate Sanchez climbs to second place in Peru vote count
-
New tools rescue old art at Madrid's Prado museum
-
Cameroonians welcome pope on second leg of African tour
-
Verstappen understands 'bigger picture' in power unit debate: F1 boss Domenicali
-
Hearn wants Katie Taylor to top Croke Park bill, rules out Fury-Joshua in Dublin
-
Stocks edge higher as investors eye chances for end of Mideast war
-
Iran ups threats over naval blockade, but still talking to US
-
Critically endangered orangutan born at Madrid zoo
-
EU rejects Meta's pay-for-access remedy in WhatsApp AI chatbots probe
-
Pupil kills four wounds 20 in new Turkey school shooting
-
Left-wing radical 'confident' after late surge in Peru presidential poll
-
Starmer says 'won't yield' to Trump's Mideast war threats
-
Liverpool captain Van Dijk says PSG 'deserved' Champions League semi-final spot
-
England women's rugby star Kildunne reveals body issues struggle
-
Chinese suppliers, Mideast importers fret about war fallout on trade
-
Markets steadier on Mideast peace hopes, as war hits luxury goods
-
EU says age-check app 'ready' in push to protect children online
-
New Hungarian leader Magyar says pro-Orban president must resign
-
After three years of war, Sudan confronts devastation as donors gather in Berlin
-
Pope heads to Cameroon with message of peace for conflict zone
-
OpenAI announces restricted-access cybersecurity model
-
England's Stokes 'quite lucky' to be alive after facial injury
-
Keiko Fujimori: Peru's biggest political loser inches toward victory
-
Barcelona hope young talent learn from Champions League disappointment
-
The Middle East war: latest developments
-
French luxury firms Hermes, Kering knocked by disappointing sales
-
Ukraine veteran stages puppet shows to honour killed soldiers
-
Afghans comb riverbed in search of gold dust
-
Stocks rally, oil falls further as Trump fans fresh peace hopes
-
Double Olympic badminton champion Axelsen announces retirement
-
Peru candidate demands vote annulment as count tightens
-
Tom Cruise shares sneak peek of Inarritu comedy 'Digger' at CinemaCon
-
Rosalia caps journey from student to star with Barcelona concerts
-
AI expansion drives up profits at bullish tech giant ASML
-
Hamano strikes as Japan end US winning streak
-
Xi meets Russian FM as leaders flock to China over Middle East war
-
'Industrial' clickbait disinformation targets Australian politics
-
AI-driven chip shortage slowing efforts to get world online: GSMA
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
